Physician
Oncology
Dr. Howard A. Burris III, MD
|
|
Give Review
Howard Burris practices Oncology. He went to medical school at University of South Alabama College of Medicine. University of South Alabama College of Medicine is ranked 83 in research and 35 in primary care medicine He over the years received 1 awards: "Fellow (FASCO)". Howard Burris is a published physician as well. He has 100 publications published. The latest was: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-a... He accepts Medicare.
Publications
- A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced Cancer.
- Atezolizumab in patients with locally advanced and metastatic urothelial Carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-a...
- Statistical Controversies in Clinical Research: Statistical significance - too much of a good thing….
- A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid Tumors.
- A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast Cancer: correlation of pathologic complete response ...
- Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negativ...
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Canc...
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic p...
- Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors.
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid Tumors.
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid Tumors.
- Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast Cancer: a Sarah Cannon Research Institute phase 1/2 trial.
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic Breast ca...
- Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid Tumors.
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder Cancer.
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
- A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory m...
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast Cancer: overall survival results from BOLER...
- Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenoCarcinoma after first-line gemcitabine therapy (PCRT O4-001).
- A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell Carcinoma.
- Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast Cancer.
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid Tumors.
- Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Ca...
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast Cancer: insights from BOLERO-2.
- Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.
- Successful Treatment With Dabrafenib (GSK2118436) in a Patient With Ganglioglioma.
- Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast Cancer.
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy.
- Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid Tumors.
- Health-Related Quality of Life and Disease Symptoms in Postmenopausal Women With HR(+), HER2(-) Advanced Breast Cancer Treated With Everolimus Plus Exemestane Versus E...
- PARP inhibitors: pitfalls and promises.
- Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid Tumors.
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup Analysis from the BOLERO-2 study.
- Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
- Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid Tumors.
- An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling ...
- A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
- Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid Tumors.
- Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
- First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement.
- Health-related quality of life of patients with advanced breast Cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomize...
- A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid Tumors.
- Overcoming acquired resistance to antiCancer therapy: focus on the PI3K/AKT/mTOR pathway.
- Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
- Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic Carcinoma of the pancreas: A Sarah Cannon Research Institute phase II...
- Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced coloRectal cancer.
- A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast Cancer.
- Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung Cancer.
- Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung Cancer.
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
- A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer.
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors.
- Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer.
- Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conju...
- A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced N...
- Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
- Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer.
- Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast Cancer: a phase II Trial of the Sarah Cannon Oncology...
- A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid Tumors.
- Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid Tumors.
- Trastuzumab Emtansine (DM1): A Novel Agent for Targeting HER2(+) Breast Cancer.
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer.
- Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast Cancer.
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies.
- A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer.
- A pilot study of adjuvant Doxorubicin and cyclophosphamide followed by Paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast Cancer.
- A phase I study of panobinostat in combination with gemcitabine in the treatment of solid Tumors.
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast Cancer after prior H...
- Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate c...
- Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid Tumors.
- A phase I study of sunitinib plus capecitabine in patients with advanced solid Tumors.
- A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced ...
- Bevacizumab and everolimus in the treatment of patients with metastatic Melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
- Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic coloRectal cancer.
- Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adju...
- Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung Cancer.
- Phase II trial of vinflunine in relapsed small cell lung Cancer.
- A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung Cancer.
- Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast Cancer.
- Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory Carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology ...
- Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: R...
- Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung Cancer.
- Phase II trial of bevacizumab and everolimus in patients with advanced renal cell Carcinoma.
- Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized Carcinoma of the esophagus or gastroesophageal...
- Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic coloRectal cancer.
- Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenoCarcinoma.
- Tracheoesophageal fistula formation in patients with lung Cancer treated with chemoradiation and bevacizumab.
- Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid Tumors.
- A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.
- Radiation recall with antiCancer agents.
- Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung Cancer.
- Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast Cancer.
- A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle ...
- A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
- A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast Cancer.
- Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cel...
Schools
University Of South Alabama
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Fellow (FASCO)
Education
-
San Antonio Uniformed Services Health Education Consortium -
University of South Alabama College of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Karl M. Rogers, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Nancy W. Peacock, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ingrid Mayer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony A. Meluch, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Igor Puzanov, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Leora Horn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert S. Cooper, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Pao, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mia A. Levy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Christina L. Derleth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Salyka M. Sengsayadeth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard S. Stein, MD |
|
|
Dr. Carl R. Willis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sally J. York, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles E. McKay, MD |